Elan upbeat despite losses

Pharmaceutical giant Elan today reported a 17% revenue increase resulting in a net loss from continuing operations of $31.8m (€24.08m) in its first-quarter 2012 financial results.

The figure includes a loss of $13.3m (€10m) from the disposal of 76% of the company’s shareholding in Alkermes plc in March 2012.